首页> 美国卫生研究院文献>Medical Journal of the Islamic Republic of Iran >Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20 CD44 P53 and Ki67
【2h】

Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20 CD44 P53 and Ki67

机译:非肿瘤性尿路上皮癌与原位尿路上皮癌的鉴别诊断:CK20CD44P53和Ki67的分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Flat urothelial lesions comprise a spectrum of morphologic changes ranging from reactive atypia to carcinoma in situ (CIS). Urothelial dysplasia and CIS are associated with the recurrence and progression of urothelial carcinoma. Distinguishing CIS and dysplasia from reactive atypia based on histolopathogical features alone is often difficult. Using different immunohistochemical markers such as Cytokeratin 20 (CK20), CD44, p53, and Ki-67 is recommended for differential diagnosis. The aim of this study was to evaluate the immunohistochemical pattern of these antibodies to differentiate different flat urothelial lesions. >Methods: In this cross- sectional study, three groups of bladder biopsy specimens were evaluated: 20 samples with reactive urothelial lesions, 20 histologically diagnosed as CIS, and 20 morphologically normal samples. Immunohistochemical staining of CK20, p53, CD44 and Ki-67 markers was performed on paraffin-embedded blocks. The groups were compared using chi square test, and the diagnostic value of the markers were evaluated with sensitivity, specificity, positive and negative predictive values. >Results: CK20 was full thickness positive in 15 (75%) CIS samples and negative in all samples of the normal and reactive groups (p<0.001); CD44 was positive in 2 (10%) cases of the CIS group and in 17 (85%) of the reactive group; this marker was negative in all the normal samples (p<0.001). P53 was positive in 12 (60%)samples of the CIS group and negative in all samples of the normal and reactive groups (p<0.001). Ki67 waspositive in 13 (65%) samples of the CIS group and 1 (5%) sample of the reactive group. This marker was negativein all samples of the normal group (p<0.001).>Conclusion: The results of this study revealed that CK20, CD44, P53 and Ki67 are useful in distinguishingCIS from reactive and normal samples. However, they should be used in a panel including at least three markers.Correlation with the morphologic features is necessary.
机译:>背景:扁平尿路上皮病变包括一系列形态学变化,范围从反应性非典型性到原位癌(CIS)。尿道上皮不典型增生和CIS与尿路上皮癌的复发和发展有关。通常仅根据组织病理学特征很难将CIS和发育异常与反应性异型症相区别。建议使用不同的免疫组化标记物,例如细胞角蛋白20(CK20),CD44,p53和Ki-67进行鉴别诊断。这项研究的目的是评估这些抗体的免疫组织化学模式,以区分不同的扁平尿路上皮病变。 >方法:在这项横断面研究中,对三组膀胱活检标本进行了评估:20例有反应性尿路上皮病变的样本,20例经组织学诊断为CIS的样本和20例形态正常的样本。在石蜡包埋的块上进行CK20,p53,CD44和Ki-67标记的免疫组织化学染色。使用卡方检验比较各组,并通过敏感性,特异性,阳性和阴性预测值评估标记物的诊断价值。 >结果:CK20在15个(75%)CIS样品中为全厚度阳性,而在正常和反应性组的所有样品中均为阴性(p <0.001); CIS组2例(10%)和反应组17例(85%)CD44阳性;在所有正常样品中,该标记均为阴性(p <0.001)。 P53阳性(12)(60%)CIS组的所有样本中,正常组和反应性组的所有样本中均为阴性(p <0.001)。 Ki67是CIS组的13个样本(65%)和反应性组的1个样本(5%)为阳性。该标记为负在正常组的所有样本中(p <0.001)。>结论:这项研究的结果表明CK20,CD44,P53和Ki67可用于区分反应性样品和正常样品的CIS。但是,应在至少包含三个标记的面板中使用它们。与形态特征相关是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号